Padcev (Enfortumab Vedotin)

Enfortumab vedotin, the active ingredient in Padcev, is an antibody‑drug conjugate presented as a sterile powder for intravenous infusion use. It treats adult patients with locally advanced or metastatic uro‑urinary tract cancer who have received prior therapy. GNH USA supplies Padcev as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Padcev as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Padcev is an antibody‑drug conjugate that targets the Nectin‑4 pathway in uro‑urinary cancers.

- Metastatic urothelial carcinoma: provides a treatment option when previous chemotherapy and PD‑1/PD‑L1 inhibitors have failed. - Locally advanced urothelial carcinoma: offers tumour shrink and disease‑control as part of a later‑stage treatment regimen. - Squamous d   

Common Side Effects: -  g 

This ...

Major ...